A review of antidepressant treatments today

European Neuropsychopharmacology

Volumn 16, Issue SUPPL. 5, 2006, Pages

  Kennedy, Sidney H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Major depressive disorder; Sexual dysfunction; Side effect burden; Sleep disruption; Weight gain

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ANXIETY DISORDER; APATHY; ARTICLE; ATYPICAL DEPRESSION; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DISEASE COURSE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MAJOR DEPRESSION; MELANCHOLIA; MOOD DISORDER; NAUSEA; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; REMISSION; SEASONAL AFFECTIVE DISORDER; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 33749642084     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(06)70007-4     Document Type: Article

References (47)

1. Ackerman S.H., and Nolan L.J. Body weight gain induced by psychotropic drugs: Incidences, mechanisms and management. C.N.S. Drugs 9 (1998) 135-151
2. Aronne L.J., and Segal K.R. Weight gain in the treatment of mood disorders. J. Clin. Psychiatry 64 (2003) 22-29
3. Bialos D., Giller E., Jatlow P., Docherty J., and Harkness L. Recurrence of depression after discontinuation of longterm amitriptyline treatment. Am. J. Psychiatry 139 (1982) 325-328
4. Campbell S., and MacQueen G. The role of the hippocampus in the pathophysiology of major depression. J. Psychiatry Neurosci. 29 (2004) 417-426
5. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., and Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry. 63 (2002) 357-366
6. Clayton A., Keller A., and McGarvey E.L. Burden of phase-specific sexual dysfunction with SSRIs. J. Affect. Disord. 91 (2006) 27-32
7. 2 receptor agonists on feeding behavior: possible mechanisms of action. Neurosci. Biobehav. Rev. 24 (2000) 341-353
8. Doraiswamy P.M., Krishnan K.R., Oxman T., Jenkyn L.R., Coffey D.J., Burt T., and Clary C.M. Does antidepressant therapy improve cognition in elderly depressed patients?. J. Psychopharmacol. 15 (2003) 173-179
9. Fava M., Judge R., Hoog S.L., Nilsson M.E., and Koke S.C. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psychiatry 61 (2000) 863-867
10. George M.S., Rush J.A., Marangell L.B., Sackeim H.A., Brannan S.K., Davis S.M., Howland R., Kling M.A., Moreno F., Rittberg B., Dunner D., Schwartz T., Carpenter L., Burke M., Ninan P., and Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol. Psychiatry 58 (2005) 364-373
11. Greenberg P.E., Kessler R.C., Birnbaum H.C., Leong S.A., Lowe S.W., Berglund P.A., and Corey-Lisle P.K. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J. Clin. Psychiatry 64 (2003) 1465-1475
12. Hasler G., Drevets W.C., Manji H.K., and Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 29 (2004) 1765-1781
13. Kalayam B., and Alexopoulos G.S. Prefrontal dysfunction and treatment response in geriatric depression. Arch. Gen. Psychiatry 56 (1999) 713-718
14. Kennedy S.H., Dickens S.E., Eisfeld B.E., and Bagby R.M. Sexual dysfunction before antidepressant therapy in major depression. J. Affect. Disord. 56 (1999) 201-208
15. Kennedy S.H., Eisfeld S.E., Meyer J.H., and Bagby R.M. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum. Psychopharmacol. 16 (2001) 105-114
16. Kennedy S.H., Holt A., and Baker G. MAOI. In: Preskorn S.H., Feighner J.P., Stanga C.Y., and Ross R. (Eds). Antidepressants: Past, Present and Future. Handbook of Experimental Pharmacology (2004), Springer Publisher Publishing Company, Heidelberg, Germany 209-239
17. Kennedy S.H., Farvolden P., Cohen N.L., Bagby R.M., and Costa Jr. P.T. The impact of personality on the pharmacological treatment of depression. In: Rosenbluth M., Kennedy S.H., and Bagby R.M. (Eds). Depression and Personality: Conceptual and Clinical Challenges (2005), American Psychiatric Publishing Inc., Washington, D.C. 97-119
18. Kennedy S.H., Anderson H.F., and Lam R.W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatr. Neurosci. 31 (2006) 122-131
19. Kennedy S.H., Fulton K.A., Bagby R.M., Greene A.L., Cohen N.L., and Rafi-Tari S. Sexual function in men and women during treatment with bupropion and paroxetine. Can. J. Psychiatry 52 (2006) 234-242
20. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, sererity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 617-627
21. Kramer J.C., Klien D.F., and Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am. J. Psychiatry 118 (1961) 549-550
22. Lam R.W., Wan D.D., Cohen N.L., and Kennedy S.H. Combining antidepressants for treatment resistant depression: a review. J. Clin. Psychiatry 63 (2002) 685-693
23. Lee A.S., and Murray R.M. The long-term outcome of Maudsley depressives. Br. J. Psychiatry 153 (1988) 741-751
24. Levkovitz Y., Caftori R., Avital A., and Richter-Levin G. The SSRIs drug fluoxetine, but not the noradrenergic tricyclic drug desipramine, improves memory performance during acute major depression. Brain Res. Bull. 58 (2002) 345-350
25. Marin H., and Menza M.A. The management of fatigue in depressed patients. Essent. Psychopharmacol. 6 (2005) 185-192
26. McIntyre R.S., Konarski J.Z., Mancini D.A., Fulton K.A., Parikh S.V., Grigoriadis S., Grupp L.A., Bakish D., Filteau M.J., Gorman C., Nemeroff C.B., and Kennedy S.H. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. Can. Med. Assoc. J. 173 (2005) 1327-1334
27. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., and Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 45 (2005) 651-660
28. Mayers A.G., and Baldwin D.S. Antidepressants and their effect on sleep. Hum. Psychopharmacol. Clin. Exp. 20 (2005) 533-559
29. Montgomery S.A., Baldwin D.S., and Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J. Affect. Disord. 69 (2002) 119-140
30. Montgomery S.A., Kennedy S.H., Burrows G.D., Lejoyeux M., and Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 19 (2004) 271-280
31. Mulder R.T., Joyce P.R., and Luty S.E. The relationship of personality disorders to treatment outcome in depressed patients. J. Clin. Psychiatry 64 (2003) 259-264
32. Nierenberg A.A., and Amsterdam J.D. Treatment resistant depression: definition and treatment approaches. J. Clin. Psychiatry 51 (1990) 39-47
33. Nofzinger E.A., Reynolds III C.F., Thase M.E., Frank E., Jennings J.R., Fasiczka A.L., Sullivan L.R., and Kupfer D.J. REM sleep enhancement by bupropion in depressed men. Am. J. Psychiatry 152 (1995) 274-276
34. Paykel E.S., Brugha T., and Fryers T. Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol. 15 (2005) 411-423
35. Quitkin F.M., McGrath P.J., Stewart J.W., Deliyannides D., Taylor B.P., Davies C.A., and Klein D.F. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J. Clin. Psychiatry 66 (2005) 670-676
36. Richelson E. Treatment of acute depression. Psychiatr. Clin. North Am. 16 (1993) 461-478
37. Rosenbaum J.F., and Zajecka J. Clinical management of antidepressant discontinuation. J. Clin. Psychiatry 58 (1997) 37-40
38. Rush J.A., Trivedi M., Carmody T.J., Biggs M.M., Shores-Wilson K., Ibrahim H., and Crismon M.L. One-year outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol. Psychiatry 56 (2004) 46-53
39. Schmitt J.A., Kruizinga M.J., and Riedel W.J. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J. Psychopharmacol. 15 (2001) 173-179
40. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., and Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3908-3913
41. Thase M.E., Kupfer D.J., Buysse D.J., Frank E., Simons A.D., McEachran A.D., Rachid K.F., and Grochocinski V.J. Electroencephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: I. Comparison during acute depressive states. Biol. Psychiatry 38 (1995) 506-515
42. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178 (2001) 234-241
43. *D: implications for clinical practice. Am. J. Psychiatry 163 (2006) 128-140
44. Üstün T.B., Ayuso-Mateos J.L., Chatterji S., Mathers C., and Murray C.J.L. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184 (2004) 386-392
45. Wager S., Robinson D., Goetz R., Nunes E., Gully R., and Quitkin F. Cholinergic REM sleep induction in atypical depression. Biol. Psychiatry 27 (1990) 441-446
46. Zajecka J., Tracy K.A., and Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J. Clin. Psychiatry 58 (1997) 291-297
47. Zimmerman M., Posternak M.A., Attiullah N., Friedman M., Boland R.J., Baymiller S., Berlowitz S.L., Rahman S., Uy K.K., Singer S., and Chelminski I. Why isn't bupropion the most frequently prescribed antidepressant?. J. Clin. Psychiatry 66 (2005) 603-610